It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The Bloom syndrome helicase BLM interacts with topoisomerase IIIα (TOP3A), RMI1 and RMI2 to form the BTR complex, which dissolves double Holliday junctions to produce non-crossover homologous recombination (HR) products. BLM also promotes DNA-end resection, restart of stalled replication forks, and processing of ultra-fine DNA bridges in mitosis. How these activities of the BTR complex are regulated in cells is still unclear. Here, we identify multiple conserved motifs within the BTR complex that interact cooperatively with the single-stranded DNA (ssDNA)-binding protein RPA. Furthermore, we demonstrate that RPA-binding is required for stable BLM recruitment to sites of DNA replication stress and for fork restart, but not for its roles in HR or mitosis. Our findings suggest a model in which the BTR complex contains the intrinsic ability to sense levels of RPA-ssDNA at replication forks, which controls BLM recruitment and activation in response to replication stress.
The BLM helicase interacts with the topoisomerase TOP3A and RMI1 to form the BTR complex. Here, the authors reveal that this complex contains multiple binding sites for the single-stranded DNA-binding complex RPA, and that RPA-binding stimulates BLM recruitment to stalled replication forks to promote their restart after replication stress.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Oxford, John Radcliffe Hospital, MRC Weatherall Institute of Molecular Medicine, Oxford, UK; Department of Oncology, University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Oxford, John Radcliffe Hospital, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5); Department of Oncology, University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University of Oxford, John Radcliffe Hospital, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5); Department of Oncology, University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); School of Environment and Society, Tokyo Institute of Technology, Department of Transdisciplinary Science and Engineering, Tokyo, Japan (GRID:grid.32197.3e) (ISNI:0000 0001 2179 2105)
4 University of Oxford, John Radcliffe Hospital, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.32197.3e); Department of Oncology, University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 University of Oxford, John Radcliffe Hospital, MRC Weatherall Institute of Molecular Medicine, Oxford, UK (GRID:grid.4991.5); Department of Oncology, University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); Yale University, Department of Molecular, Cellular and Developmental Biology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
6 Department of Oncology, University of Oxford, MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948); University of Oxford, Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
7 University of Oxford, Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)